Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

GlobeNewswire December 20, 2018

Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

GlobeNewswire December 19, 2018

B. Riley Financial Enters a Definitive Agreement to Purchase Fortress Biotech’s Stake in National Holdings Corporation

GlobeNewswire November 19, 2018

Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial

GlobeNewswire November 19, 2018

B. Riley Financial Enters Agreement to Purchase Fortress Biotech’s Stake in National Holdings

GlobeNewswire November 19, 2018

InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

GlobeNewswire November 13, 2018

Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire November 9, 2018

Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope

GlobeNewswire October 30, 2018

Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire October 15, 2018

Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa

GlobeNewswire October 1, 2018

Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference

GlobeNewswire September 27, 2018

National Announces Expansion of Equity Research Team

GlobeNewswire September 27, 2018

Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development

GlobeNewswire September 12, 2018

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

GlobeNewswire September 6, 2018

Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

GlobeNewswire September 4, 2018

Mustang Bio to Participate in September Investor Conferences

GlobeNewswire August 30, 2018

Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 30, 2018

National Holdings Corporation Announces Expansion of Capital Markets Team

GlobeNewswire August 20, 2018

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2018

Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 13, 2018